
Teva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy
Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd.and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.today announced a significant strategic partnership for the development and eventual commercial delivery of…